{
    "clinical_study": {
        "@rank": "75659", 
        "arm_group": {
            "arm_group_label": "Study patients", 
            "description": "Patients receiving unfractionated heparin (UFH)"
        }, 
        "brief_summary": {
            "textblock": "To demonstrate the substantial equivalence (SE) of Pefakit\u00ae PiCT\u00ae UC (test device, T) to\n      aPTT-SP (Hemosil) (predicate device, P) in determining heparin levels in subjects undergoing\n      heparin therapy in support of a United States Food and Drug Administration (FDA) 510(k)\n      submission."
        }, 
        "brief_title": "Clinical Performance Evaluation of Pefakit\u00ae PiCT\u00ae UC In Vitro Diagnostic Medical Device", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Thromboembolic Events", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Embolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "Standard of Care Study. Objective is to monitor the patients' heparin levels under treatment\n      with continuous unfractionated heparin infusions. Blood samples collections (4 ml) are\n      required routinely. A proportion of this standard sample (leftover plasma) will be used for\n      study purposes. About three samples will be analyzed which are collected within 2 - 4 days.\n      Time points for blood sample collections will be defined by the treating physician according\n      the local standard of care and will be associated exclusively to clinical considerations.\n      Results of the Pefakit\u00ae PiCT\u00ae UC assay will NOT be used to take therapeutic decisions for\n      study subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects receiving a continuous infusion with UFH\n\n          -  Subjects who have given written informed consent (unless written informed consent is\n             waived by local regulations or local EC/IRB)\n\n        Exclusion Criteria:\n\n          -  Subjects treated with any other anticoagulants other than UFH\n\n          -  Subjects who have been undergoing fibrinolytic therapy within the previous 4 weeks\n\n          -  Subjects who are known to have a congenital bleeding disorder\n\n          -  Subjects known to present unexplained prolongations of clotting time\n\n          -  Subjects known to have coagulation factor deficiencies\n\n          -  Patient participating or who has participated within one month from enrolment in\n             another investigational study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects undergoing UFH anticoagulation therapy will are needed for this study. Typically,\n        such patients are undergoing cardiovascular surgery, are being treated for thromboembolic\n        events, or are receiving heparin intravenously for thrombosis prophylaxis due to its more\n        advantageous pharmacokinetic profile in some situations."
            }
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052544", 
            "org_study_id": "PICT-01"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "determination of heparin levels", 
            "Patients", 
            "requiring", 
            "unfractionated"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "65191"
                    }, 
                    "name": "Deutsche Klinik f\u00fcr Diagnostik"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Cantonal Hospital -Institue for Clinical Chemistry and hematology"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Clinical Performance Evaluation of Pefakit\u00ae PiCT\u00ae UC In Vitro Diagnostic Medical Device", 
        "overall_official": [
            {
                "affiliation": "Deputy Head Institute for Clinical Chemistry and Hematology", 
                "last_name": "Wolfgang Korte", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Deutsche Klinik f\u00fcr Diagnostik GmbH", 
                "last_name": "Manuela K. Krause, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Oklahoma Health Sciences Center- Department of Medicine", 
                "last_name": "Rathbun Suman, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Determining heparin levels in subjects undergoing heparin therapy in support of a United States Food and Drug Administration (FDA) 510(k) submission.", 
            "measure": "Clotting times versus UFH concentrations.", 
            "safety_issue": "No", 
            "time_frame": "within 2 - 4 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052544"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "DSM Nutritional Products, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DSM Nutritional Products, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}